Glaukos ( (GKOS) ) has issued an update.
Glaukos Corporation reported a successful third quarter for 2024, with record net sales of $96.7 million, marking a 24% increase from the previous year. The company’s glaucoma segment saw a 30% rise in sales, contributing to the strong financial performance. Despite a net loss of $21.4 million, Glaukos raised its 2024 net sales guidance, reflecting its confidence in ongoing strategic plans and the advancement of its innovative therapies for eye diseases.
See more insights into GKOS stock on TipRanks’ Stock Analysis page.
